A Phase 1/2 interventional study of Probiotic Supplementation (Lactobacillus plantarum) and Placebo Tablets in Kidney Disease, Chronic, Renal Insufficiency, Chronic and Gut Dysbiosis, sponsored by Mansoura University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Mansoura University · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies in Renal Insufficiency, Chronic with a site in Egypt — 23 open to participants now, 28 under way, 4 of them phase 3. Renal Insufficiency, Chronic · Egypt.
Among the 64 studies in Renal Insufficiency, Chronic with a site in Egypt, this one is the 20th largest by planned enrollment of the 44 interventional ones that give a count, is one of 17 that started in 2025, is one of 2 in phase 1/2, reaches primary completion later than 6 of the 27 other live ones, and was the 35th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →23 of the 64 studies in Renal Insufficiency, Chronic with a site in Egypt are open now. Recruiting first, the newest first:
Badr University · Sites in Egypt
Ages 36–58
Future University in Egypt · Sites in Egypt
Ages 18+
Ace Cells Lab Limited · Sites in Egypt
Ages 18–80
Sohag University · Sites in Egypt
Ages 18+
Ain Shams University · Sites in Egypt
Ages 18+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 8 · Phase 4 8
First in 2013; this study’s year is marked. 17 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 72 is close to the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 64 across the 44 interventional studies, 110 across the 20 observational. Of the 29 that completed or were terminated, 1 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 64 have an industry lead sponsor. The 10 most frequent:
Mansoura University is the lead sponsor of 1,121 studies on the registry; 183 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Mansoura University has 7 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
6 of the studies in Renal Insufficiency, Chronic with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07706582Beni-Suef UniversityManagement of Iron Deficiency Anemia in Hemodialysis Patients | 2026-12 |
| NCT03436368Nazmy Edward SeifContinuous Spinal Anesthesia in Renal Transplantation | 2026-12 |
| NCT03778944Nazmy Edward SeifEnhancing Renal Graft Function During Donor Anesthesia | 2026-12 |
| NCT07640919Sohag UniversityPatterns of Cardiac Arrhythmia in Patients With Chronic Kidney Disease | 2026-12-20 |
| NCT07235891Alexandria UniversityRetinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease | 2026-12-20 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies in Renal Insufficiency, Chronic with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn whether probiotic supplementation can slow disease progression in patients with moderate to severe chronic kidney disease (CKD). The trial will also assess the safety of probiotics in these patients.
The main questions the study aims to answer are:
Does probiotic supplementation improve kidney function by reducing serum creatinine levels and protein in urine? Does it reduce inflammation and metabolic imbalances in CKD patients? Does it affect gut microbiota composition and lower harmful toxins in the body? Is probiotic supplementation safe and well-tolerated in CKD patients?
Participants will:
Be randomly assigned to receive either probiotics or a placebo for 6 months. Have clinic visits every 6 months for checkups, blood tests, and urine tests. Be monitored for any side effects and changes in kidney function. Researchers will compare the probiotic group to the placebo group to determine whether probiotics are effective in slowing CKD progression.
Background \& Rationale:
Chronic Kidney Disease (CKD) is associated with significant alterations in gut microbiota, leading to the production and accumulation of uremic toxins such as indoxyl sulfate (IS) and p-cresyl sulfate (PCS). These toxins contribute to systemic inflammation, oxidative stress, and accelerated kidney disease progression, ultimately increasing cardiovascular mortality. The disruption of gut barrier function and dysbiosis are major contributing factors in CKD pathophysiology.
Probiotic supplementation has been proposed as an adjuvant therapy to modulate gut microbiota, enhance intestinal barrier integrity, and reduce systemic inflammation. Probiotics, particularly Lactobacillus species, have been shown to ferment dietary fiber, produce beneficial metabolites, and competitively inhibit harmful bacteria. Despite some promising findings, prior clinical trials have reported inconsistent results, necessitating further investigation into the efficacy of probiotics in slowing CKD progression.
This randomized, double-blind, placebo-controlled clinical trial aims to assess the impact of probiotic supplementation on renal function, systemic inflammation, and gut-derived uremic toxins in patients with moderate to severe CKD (Stages III-IV).
Study Design \& Methodology This trial is a parallel-group, double-blind, randomized controlled study with a 1:1 allocation ratio. Participants will be recruited from the Urology and Nephrology Center, Mansoura University, and randomized into either the probiotic intervention group or the placebo control group.
Intervention Details:
Study Group: Participants will receive probiotic supplementation (Lactogemikan; Pescado Pharmaceuticals, Egypt), containing 10 billion CFU of Lactobacillus plantarum per tablet. The dose will be one tablet daily for 6 months.
Control Group: Participants will receive an identical placebo tablet for 6 months.
Both groups will be followed up for an additional 6 months after treatment cessation to evaluate any persistent effects of probiotic supplementation.
Primary \& Secondary Outcomes:
The trial will measure:
Primary Outcomes:
Changes in serum creatinine, estimated glomerular filtration rate (eGFR), and urinary protein levels over 12 months.
Secondary Outcomes:
Changes in systemic inflammatory markers (C-reactive protein, ferritin, total cholesterol, albumin).
Alterations in gut microbiota composition, assessed by urinary indican (indoxyl sulfate) levels before and after treatment.
Evaluation of safety and tolerability of probiotic supplementation in CKD patients.
Randomization \& Blinding:
Randomization: Conducted via a computerized random sequence generator.
Blinding:
Double-blinded (both participants and investigators are blinded to group assignments).
The probiotic and placebo tablets are identical in appearance, taste, and packaging.
Follow-Up \& Monitoring:
Participants will be evaluated at three time points:
Baseline assessment (before treatment initiation) 6-month follow-up (after completing treatment) 12-month follow-up (6 months post-treatment cessation) At each visit, clinical, biochemical, and microbiota assessments will be conducted. Any adverse events will be documented.
Statistical Analysis Plan Data will be analyzed using R statistical software (R Core Team, 2023).
Descriptive statistics will summarize baseline characteristics. Continuous variables will be assessed using the Shapiro-Wilk test for normality.
Depending on normality:
Welch's t-test (normally distributed variables) Mann-Whitney U test (non-normally distributed variables) Categorical variables will be analyzed using the Chi-square test. A p-value \< 0.05 will be considered statistically significant. Ethical Considerations \& Regulatory Compliance Ethical Approval: The study has been approved by the Institutional Review Board (IRB) of Mansoura Faculty of Medicine, Mansoura University (IRB Code: MD.24.06.864).
Informed Consent: All participants will provide written informed consent before enrollment.
Adverse Events Reporting: Any serious adverse events (SAEs) will be immediately reported to the IRB and Ethics Committee.
Confidentiality: Participant data will be anonymized and stored securely. Significance of the Study This study aims to provide new insights into the therapeutic role of probiotics in CKD patients. If effective, probiotic supplementation may offer a low-cost, non-invasive adjunct therapy to slow kidney disease progression, reduce inflammation, and improve metabolic health.
By investigating the mechanistic role of probiotics in modulating gut-derived toxins, this trial may contribute to developing novel microbiome-targeted interventions in nephrology practice.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this group will receive Lactogemikan (Probiotic Supplement), which contains 10 billion CFU of Lactobacillus plantarum per tablet. They will take one tablet daily for 6 months. The purpose of this intervention is to evaluate whether probiotic supplementation can slow the progression of chronic kidney disease (CKD) by modulating gut microbiota, reducing systemic inflammation, and decreasing uremic toxin levels. Participants will be monitored through clinical visits and laboratory tests at baseline, and 6 months to assess kidney function (eGFR, serum creatinine, urinary protein levels), inflammatory markers (CRP, ferritin, albumin), and gut microbiota composition (urinary indican levels).
Drug: Probiotic Supplementation (Lactobacillus plantarum)
Participants in this group will receive a placebo tablet that is identical in appearance, taste, and packaging to the probiotic supplement but contains no active probiotic ingredients. They will take one tablet daily for 6 months. This group serves as a control to compare the effects of probiotic supplementation against a non-active intervention. Participants will undergo the same clinical visits and laboratory assessments as the intervention group at baseline, and 6 months. Outcomes assessed will include kidney function (eGFR, serum creatinine, urinary protein levels), systemic inflammation markers (CRP, ferritin, albumin), and gut microbiota composition (urinary indican levels) to determine whether the probiotic has a measurable impact compared to the placebo.
Participants in this group will receive Lactogemikan (Probiotic Supplement), which contains 10 billion CFU of Lactobacillus plantarum per tablet. The dose is one tablet daily for 6 months. This probiotic is intended to modulate gut microbiota, reduce systemic inflammation, and decrease uremic toxins (indoxyl sulfate) in CKD patients. The intervention will be compared to a placebo to evaluate its effectiveness in slowing CKD progression and improving metabolic and inflammatory markers.
Participants in this group will receive an inert placebo tablet that is identical in appearance, taste, and packaging to the probiotic supplement but contains no active probiotic ingredients. The dose is one tablet daily for 6 months. The placebo serves as a control to compare the effects of the probiotic intervention. Both groups will undergo identical monitoring and follow-up assessments to determine whether the probiotic has a significant effect on kidney function, inflammation, and gut microbiota composition.
Change in Estimated Glomerular Filtration Rate (eGFR)
eGFR will be calculated using the CKD-EPI 2021 equation to assess changes in kidney function over time. A slower decline in eGFR in the probiotic group compared to the placebo group would indicate a beneficial effect.
Time frame: Baseline, and 6 months
Change in Gut-Derived Uremic Toxins (Indoxyl Sulfate)
Urinary indican (indoxyl sulfate) levels will be measured to assess whether probiotics alter gut microbiota composition and reduce uremic toxin production.
Time frame: Baseline, and 6 months
Plan to share: No — Due to patient confidentiality and ethical considerations, individual participant data (IPD) will not be shared.
Started Apr 2025 (actual). Primary completion is estimated for Oct 2025, 6 months after the start.
Of 22 phase 1/2 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 55. This study's planned 6 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lactobacillus plantarum
Renal Insufficiency, Chronic →